Uremic Toxins and Lipases in Haemodialysis: A Process of Repeated Metabolic Starvation

Stegmayr, Bernd
May 2014
Toxins;May2014, Vol. 6 Issue 5, p1505
Academic Journal
Severe kidney disease results in retention of uremic toxins that inhibit key enzymes for lipid breakdown such as lipoprotein lipase (LPL) and hepatic lipase (HL). For patients in haemodialysis (HD) and peritoneal dialysis (PD) the LPL activity is only about half of that of age and gender matched controls. Angiopoietin, like protein 3 and 4, accumulate in the uremic patients. These factors, therefore, can be considered as uremic toxins. In animal experiments it has been shown that these factors inhibit the LPL activity. To avoid clotting of the dialysis circuit during HD, anticoagulation such as heparin or low molecular weight heparin are added to the patient. Such administration will cause a prompt release of the LPL and HL from its binding sites at the endothelial surface. The liver rapidly degrades the release plasma compound of LPL and HL. This results in a lack of enzyme to degrade triglycerides during the later part of the HD and for another 3-4 h. PD patients have a similar baseline level of lipases but are not exposed to the negative effect of anticoagulation.


Related Articles

  • Report: New ESRD Cases Decline. CHARNOW, JODY A. // Renal & Urology News;Feb2014, Vol. 13 Issue 2, p1 

    The article reports on the data from the U.S. Renal Data System which shows the declined numbers of new patients starting end-stage renal disease (ESRD) therapy and initiating therapy on hemodialysis from 2010-2011. The decline which is believed to be related with the new bundled payment system,...

  • Criteria for selection of ESRD treatment modalities. Mazzuchi, Nelson; Fernandez-Cean, Juan M.; Carbonell, Enriqueta // Kidney International Supplement;Jan2000, Issue 74, pS-136 

    Provides information about the criteria for selection of end-stage renal disease (ESRD) treatment modalities. Treatment modalities for ESRD; Factors in selecting the best renal replacement therapy for patients.

  • Using peritoneal dialysis as an immediate start treatment. Endall, Gerry; Hawes, Scott // Journal of Renal Nursing;2012, Vol. 4 Issue 6, p300 

    The article focuses on a study related to the use of peritoneal dialysis (PD) as a first-line dialysis treatment. The study informs that the use of the Wessex Renal and Transplantation Service (WRTS) offer peritoneal dialysis in patients with a need for immediate treatment. The study mentions...

  • TREATMENT OPTIONS FOR CHRONIC KIDNEY DISEASE.  // For the Record (Great Valley Publishing Company, Inc.);6/20/2011, Vol. 23 Issue 12, p28 

    The article focuses on the codes for the treatment options for chronic kidney disease (CKD) in the U.S. Hemodialysis is considered the most common option for CKD with the International Classification of Disease-Ninth Revision-Clinical Modification (ICD-9-CM) code 39.95. Kidney transplantation is...

  • Peritoneal Dialysis: Does It Have a Brighter Future? Mehrotra, Rajnish // Renal & Urology News;Nov2010, Vol. 9 Issue 11, p10 

    The article focuses on the peritoneal dialysis (PD) as a long-term treatment for PD patients. It states that since its application for the treatment of uremia is a failure, three major advances were made including an indwelling intraperitoneal catheter, and the description of constant...

  • Gastrointestinal Symptoms in Patients With End-Stage Renal Disease Undergoing Treatment by Hemodialysis or Peritoneal Dialysis. Cano, Alicia E.; Neil, Ailsa K.; Kang, Jin-Yong; Barnabas, Ashley; Eastwood, John B.; Nelson, Stephen R.; Hartley, Ian; Maxwell, Douglas // American Journal of Gastroenterology;Sep2007, Vol. 102 Issue 9, p1990 

    OBJECTIVES: The aim of this study was to determine the prevalence of gastrointestinal symptoms in patients with end-stage renal disease undergoing hemodialysis (HD) or peritoneal dialysis (PD) treatment. METHODS: Patients undergoing HD or chronic ambulatory PD in the Department of Renal Medicine...

  • Mortality Is Significantly Higher in Heart Transplant Patients with ESRF.  // Kidney;Jul/Aug99, Vol. 8 Issue 4, p146 

    Compares the results of treatment with hemodialysis, peritoneal dialysis, or renal transplantation in heart transplant recipients with end-stage renal failure (ESRF). Mortality rate of heart transplant recipients undergoing different therapeutic modalities; Risk of death of heart transplant...

  • PERITONEAL DIALYSIS - EXPERIENCES. MIRKOVIĆ, Tatjana ÐURÐEVIĆ // Medicinski Pregled / Medical Review;2010, Vol. 63 Issue 11/12, p753 

    No abstract available.

  • Daily hemodialysis and caregivers burden. Rutkowski, Bolesław; Rychlik, Ivan // Nephrology Dialysis Transplantation;Jul2011, Vol. 26 Issue 7, p2074 

    No abstract available.


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics